Consensus recommendations for neurofibromatosis type 1 management in Asia Pacific.

Yemima Berman, Beom Hee Lee, Anthony Pak-Yin Liu, Yoshihiro Nishida, Ee Shien Tan, Zhichao Wang, APAC NF1 Expert Panel

Abstract read

In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yemima BermanKolling Institute, Northern Sydney Local Health District and the Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.

Beom Hee LeeDepartment of Paediatrics, Medical Genetics Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Anthony Pak-Yin LiuDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China.

Yoshihiro NishidaDepartment of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.

Ee Shien TanGenetics Service, KK Women's and Children's Hospital, Singapore, Singapore.

Zhichao WangDepartment of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

APAC NF1 Expert Panel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is a complex multisystem disorder requiring coordinated multidisciplinary care. This study aimed to develop consensus recommendations for NF1 management in the Asia-Pacific region. A modified Delphi process involving two survey rounds and a virtual meeting was conducted with experts from nine countries. A total of 141 statements were evaluated using a 9-point Likert scale with a 75% consensus threshold. Consensus was achieved across key domains including diagnosis, genetic testing, surveillance, and management. Experts emphasized the importance of multidisciplinary care, risk-adapted surveillance, and integration of genetic counseling and imaging in clinical practice. These findings provide regionally relevant guidance to support consistent and practical NF1 management across diverse healthcare systems.

Indexed as

ANNUBPmalignant peripheral nerve sheath tumorMPNSTneurofibromatosis type 1NF1plexiform neurofibromatumor surveillance

Identifiers

PMID42866620

DOI10.1016/j.isci.2026.117002

PMCPMC13657100

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.